There's plenty to chew on in Venture Global's IPO filing beyond just the topline numbers. Why it matters: The U.S. LNG ...

Venture Global is seeking up to $110.38 billion valuation in its New York initial public offering, the second-largest U.S.

Fintech giant Groww is reportedly gearing up to file for an initial public offering (IPO) in the next 10-12 months ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Antharas said it expects the IPO to price between $4 and $5 per share. The company applied to list on the Nasdaq Capital Market under the symbol AAS. For the year ended Dec. 31, 2023, the company ...

Titan America SA, the US unit of Titan Cement International SA, has filed for an initial public offering in New York, showing ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

It would be the first life sciences IPO since BioAge Labs' offering in September. Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of ...

Titan America, a manufacturer and supplier of heavy building materials and services, plans to sell shares through an initial public offering, according to a Securities and Exchange Commission filing ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

Gold jewellery maker Shanti Gold International has filed preliminary papers with SEBI to raise funds via initial public ...

The IPO, with an equity share face value of ₹10, consists entirely of a fresh issuance of up to 18 million equity shares.